BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

842 related articles for article (PubMed ID: 20587519)

  • 21. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
    Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
    Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
    Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
    Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
    Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity.
    Qi J; Tripathi M; Mishra R; Sahgal N; Fazli L; Ettinger S; Placzek WJ; Claps G; Chung LW; Bowtell D; Gleave M; Bhowmick N; Ronai ZA
    Cancer Cell; 2013 Mar; 23(3):332-46. PubMed ID: 23518348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination.
    Printsev I; Yen L; Sweeney C; Carraway KL
    J Biol Chem; 2014 Mar; 289(12):8570-8. PubMed ID: 24519943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
    Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
    Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
    Yang JC; Ok JH; Busby JE; Borowsky AD; Kung HJ; Evans CP
    Cancer Res; 2009 Jan; 69(1):151-60. PubMed ID: 19117998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
    Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
    Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
    Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Naito S
    Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
    Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
    Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.
    Ribas J; Ni X; Haffner M; Wentzel EA; Salmasi AH; Chowdhury WH; Kudrolli TA; Yegnasubramanian S; Luo J; Rodriguez R; Mendell JT; Lupold SE
    Cancer Res; 2009 Sep; 69(18):7165-9. PubMed ID: 19738047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.